期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

过氧化物酶体增殖物激活受体与脂肪性肝病的关系 被引量：1

暂未订购
导出
摘要 脂肪性肝病是由于脂质代谢紊乱造成脂肪在肝脏内沉积而出现的多种病理生理学改变,主要包括单纯性脂肪肝、脂肪性肝炎、脂肪性肝纤维化,以及其进一步发展的肝硬化和肝细胞癌。过氧化物酶体增殖物激活受（pemxisome proliferator activated receptors PPARs）是1990年在研究小鼠肝脏cDNA文库时发现的，一种新的同醇类激素受体,因其能被一类脂肪酸样化合物过氧化物酶体增殖剂激活而得名。
作者 金文君
机构地区 浙江省湖州市中心医院检验科
出处 《实验与检验医学》 CAS 2008年第1期65-66,共2页 Experimental and Laboratory Medicine
关键词 过氧化物酶体增殖物激活受体 脂肪性肝病 过氧化物酶体增殖剂 病理生理学改变 脂肪性肝纤维化 脂质代谢紊乱 单纯性脂肪肝 cDNA文库
分类号 R587.1 [医药卫生—内分泌] R575.5 [医药卫生—消化系统]
  • 相关文献

参考文献14

  • 1[1]Zafrani ES.Non-alcoholic fatty liver disease,an emerging pathological spectrum[J].Progress in lipid Res,2001,40(4):269～281.
  • 2张乾勇.PPAR的结构与功能及其生物学作用[J].国外医学（卫生学分册）,2000,27(5):284-288. 被引量：21
  • 3施军平,陈芝芸,包剑锋,何蓓晖,严茂祥,荀运浩.高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织PPARα和CPT-ⅠmRNA的表达[J].浙江中医药大学学报,2007,31(1):52-55. 被引量：10
  • 4孙龙,迟宝荣,张填,王春妍.过氧化物酶体增殖物激活受体-α与肝脏疾病的关系[J].新医学,2007,38(2):127-129. 被引量：8
  • 5[5]Reddy JK Ⅲ Nonalcoholic steatosis and steatohepatitis.peroxisomal beta-oxidation PPAR alpha and steatohepatitis[J].Am J Physiol Gastrointest Liver Physiol,2001,281(6):G1333～G1339.
  • 6[6]IP E,Farrell G C Robea song et al.Central roke of PPAR alpha dependent hepatic lipid turnover in dietary steatohepatitis in mice[J].Hepatology,2003,38(1):123～132.
  • 7[7]Everett L,Galli A,Grabb D.The role of hepatic peroxisome prolif-erator-activated receptors(PPSRs) in health and disease[J].Liver,2000,20:191～199.
  • 8[8]Lee SS,Chan WY,Lock,et al.Requirement of PPAR alpha in maintaining phospholipid and triacylglycerol homeostasis dudng en-ergy deprivation[J].J Lipid Res,2004,45(11):2025～2037.
  • 9赵彩彦,姜玲玲.过氧化物酶体增殖物激活受体与肝病的关系[J].中华肝脏病杂志,2003,11(6):382-384. 被引量：7
  • 10[10]Minnich A,Tian N,Byan L,et al.A potent PPAR alpha agonost-stimulates mitochondfial fatty acid beta-oxidaation in liver and skeletal muscle[J].Am J Physiol Endocrinol Metab,2001,280～2702.

二级参考文献24

  • 1YEPing WANGZhao-jun ZHANGXiu-jin ZHAOYa-li.Age-related decrease in expression of peroxisome proliferator-activated receptor α and its effects on development of dyslipidemia[J].Chinese Medical Journal,2005(13):1093-1098. 被引量：10
  • 2石如玲,姜玲玲.胆汁酸对大鼠肝脏过氧化物酶体增殖剂激活受体αmRNA表达的影响[J].河北医科大学学报,2005,26(5):368-369. 被引量：2
  • 3Hart C, Demetris AJ, Michalopoulos G, et al. 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells . Am J Physiol Gastrointest Liver Physiol, 2002,282: G586-597.
  • 4Everett L, Galli A, Grabb D. The role of hepatic peroxisome proliferator -activated receptors (PPARs) in health and disease. Liver,2000, 20: 191-199.
  • 5Reddy JK. III Nonalcoholic steatosis and steatohepatitis. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol, 2001, 281 : G 1333-1339.
  • 6Fan CY, Pan J, Usuda N, et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferaroractivated receptor alpha natural ligand metabolism. J Biol Chem,1998, 273: 15639-15645.
  • 7Clarke SD. Nonalcoholic steatosis and steatohepatitis. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol, 2001, 281:G865-869.
  • 8Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis, 2001, 21: 27-41.
  • 9Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAY mice exhibit increased hepatic PPAR gammal gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J hepatol, 2001, 35: 17-23.
  • 10Kon K, Ikejima K, Hirose M, et al. Pioglitazone prevents earlyphase hepatic fibrogenesis caused by carbon retrachloride. Biochem Bilphys Res Commun, 2002, 291: 55-61.

共引文献41

同被引文献18

  • 1郭美祥,田晓娟,李文彪.过氧化物酶体增殖物激活受体与酒精性肝病关系研究进展[J].中西医结合肝病杂志,2006,16(5):306-308. 被引量：1
  • 2黎玉.酒精性脂肪肝分子机制的研究进展[J].中华肝脏病杂志,2006,14(11):878-880. 被引量：10
  • 3Keller JM,Collet P,Bianchi A,et al.Implications of peroxisome proliferator-activated receptors(PPARS)in development,cell life status and disease[J].Int J Dev Biol,2000,44(5):429-442.
  • 4Kong L,Ren W,Li W,et al.Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice[J].Lipids Health Dis,2011(10):246.
  • 5Konig B,Koch A,Spielmann J,et al.Activation of PPAR alpha lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2[J].Biochem Pharmacol,2007,73(4):574-585.
  • 6Nan YM,Kong LB,Ren WG,et al.Activation of peroxisome proliferator activated receptorαameliorates ethanol mediated 1iver fibrosis in mice[J].Lipids Health Dis,2013(12):21.
  • 7Lebrun V,Molendi-Coste O,Lanthier N,et al.Impact of PPAR-αinduction on glucose homoeostasis in alcohol-fed mice[J].Clin Sci(Lond),2013,125(11):501-511.
  • 8Nakajima T,Kamijo Y,Tanaka N,et al.Peroxisome proliferatoractivated receptor a protects against alcohol-induced liver damage[J].Hepatology,2004,40(4):972-980.
  • 9Sahebkar A,Chew GT,Watts GF.New peroxisome proliferator-activated receptor agonists:potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease[J].Exper Opin Pharmacother,2014,15(4):493-503.
  • 10Ga Ili A,Pinaire J,Fischer M,et al.The transcrip tional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism.A nove1 mechanism for the development of ethanol-induced fatty liver[J].J Biol Chem,2001,276(1):68-75.

引证文献1

二级引证文献2

实验与检验医学
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部